Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab

License For Prolia And Xgeva Rivals Follows Ustekinumab Deal With Bio-Thera

 
• By Dave Wallace

Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.

Building A Brick Wall, Bricklayers
The next piece has fallen into place for Hikma’s US biosimilars business • Source: Alamy

More from Deals

More from Business